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SURGERY FOR ACQUIRED 
HEART DISEASE 
EARLY OUTCOME OF 
MITRAL VALVE 
RECONSTRUCTION IN 
PATIENTS WITH END-STAGE 
CARDIOMYOPATHY 
Uncontrollable severe mitral regurgitation is a frequent complication of end-stage 
cardiomyopathy, significantly contributing to heart failure in these patients, and 
predicts a poor survival. Although elimination of mitral valve regurgitation could be 
most beneficial in this group, corrective mitral valve surgery has not been routinely 
undertaken i  these very ill patients because of the presumed prohibitive operative 
mortality. We studied the early outcome of mitral valve reconstruction in 16 
consecutive patients with cardiomyopathy and severe, refractory mitral regurgita- 
tion operated on between Jnne 1993 and April 1994. There were 11 men and five 
women, aged 44 to 78 years (64 - 8 years) with left ventricular ejection fractions of 
9% to 25% (16% +-- 5%). Preoperatively all patients were in New York Heart 
Association class IV, had severe mitral regurgitation (graded 0 to 4+ according to 
color flow Doppler transesophageal echocardiography) and two were listed for 
transplantation. Operatively, a flexible annuloplasty ring was implanted in all 
patients. Four patients also had single coronary bypass grafting for incidental 
coronary disease. In four patients the operation was performed through a right 
thoracotomy because of prior coronary bypass grafting, and four patients also 
underwent ricuspid valve reconstruction for severe tricuspid regurgitation. No 
patient required support with an intraaortic balloon pump. There were no operative 
or hospital deaths and mean hospital stay was 10 days. There were three late deaths 
at 2, 6, and 7 months after mitral valve reconstruction, and the 1-year actuarial 
survival has been 75%. At a mean follow-up of 8 months, all remaining patients are 
in New York Heart Association class I or II, with a mean postoperative ejection 
fraction of 25% -+ 10%. There have been no hospitalizations for congestive heart 
failure, and a decrease in medications required has been noted. For patients with 
cardiomyopathy and severe mitral regurgitation, mitral valve reconstruction as 
opposed to replacement can be accomplished with low operative and early mortality. 
Although longer term follow-up is mandatory, mitral valve reconstruction may allow 
new strategies for patients with end-stage cardiomyopathy and severe mitral 
regurgitation, yielding improvement in symptomatic status and survival. (J THORAC 
CARDIOVASC SURG 1995;109:676-83) 
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M itral regurgitation is a significant complication 
of end-stage cardiomyopathy, thought to be 
due to dilation of the mitral annular-ventricular 
apparatus 1, 2 with altered ventricular geometry 3 or 
due to ischemic papillary muscle dysfunction. 2 Mi- 
tral regurgitation leads to a cycle of more volume 
ovedoad of the already dilated left ventricle (LV), 4 
with progressive annular dilation, worsened mitral 
regurgitation, and congestive heart failure. Finally, 
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uncontrollable severe mitral regurgitation, refrac- 
tory to medical therapy, is a late complication of 
cardiomyopathy and predicts a poor survival. 5 A1- 
though cardiac transplantation has encouraging 
results for these patients with end-stage cardiomy- 
opathy, transplantation is hindered by donor organ 
shortage and its limited applicability to older pa- 
tients and patients with concurrent disease. As an 
alternative, surgical correction of mitral valve regur- 
gitation could be most beneficial in this group. 
However, mitral valve replacement has not been 
routinely contemplated because of the presumed 
prohibitive operative mortality in these very ill pa- 
tients. 6s Mitral valve replacement is associated with 
a postoperative loss of LV systolic function 9' 10 
because of interruption of annular-chordal-papil- 
lary muscle continuity, n' 12 This loss of ventricular 
function, poorly afforded in patients with cardio- 
myopathy, may be responsible for the high operative 
mortality and poor late survival 1»-15 in patients with 
LV dysfunction undergoing mitral valve replace- 
ment. Conversely, reconstruction of the mitral valve 
with preservation of annular-chordal-papillary 
muscle continuity 16 results in maintenance of LV 
systolic function, lower LV volumes, and less end- 
systolic wall stress 17' 18 and has a lower mortality 
than mitral valve replacement. 19'2o Hypothetically, 
worsening heart failure in patients with dilated 
cardiomyopathy, resulting from annular dilation and 
mitral regurgitation, could be stabilized or improved 
by correction of mitral regurgitation, and preserving 
mitral anulus-chordal integrity by mitral recon- 
struction could yield acceptable operative and post- 
operative mortality. This present study was designed 
to assess the feasibility of mitral valve reconstruction 
for mitral regurgitation caused by dilated cardio- 
myopathy and to monitor the early outcome of 
mitral valve reconstruction i  terms of survival, 
impact on heart failure, and LV function. 
Methods 
Between June 1993 and April 1994, 16 consecutive, 
nonrandomized patients at the University of Michigan 
Medical Center, with end-stage dilated cardiomyopathy 
and refractory severe mitral regurgitation, were studied 
prospectively. All patients had New York Heart Associa- 
tion (NYHA) class III or IV congestive heart failure, 
despite receiving maximized medical regimens, and had 
severe LV systolic dysfunction defined as an ejection 
fraction of less than 25% on LV angiography or radionu- 
clide angiography. Patients were excluded from this study 
if they had evidence of primary mitral valvular disease, if 
significant mitral regurgitation preceded cardiomyopathy, 
if surgical intervention i cluded revascularization f via- 
bie myocardium, or if they had significant aortic insutti- 
ciency. 
Eehocardiographic imaging. All preoperative and post- 
operative chocardiographic imaging was performed with 
standard transthoracic windows with commercially avail- 
able equipment, including Acuson 128XP/10 (Acuson, 
Inc., Mountain View, Calif.) and Hewlett-Packard Sonos 
1000 (Hewlett-Packard Company, Waltham, Mass.) echo- 
cardiographs. Intraoperative echocardiography was per- 
formed with a Hewlett-Packard Sonos 1500 echocardio- 
graph and biplane transesophageal probe. All images 
were recorded on standard VHS videotape. Quantitative 
analysis was performed by a single experienced echocar- 
diographer blinded at the time of analysis to clinical data. 
Mitral regurgitation was assessed by color fiow Doppler 
echocardiography; severity was graded as mild, moderate, 
or severe. 21 Quantitative echocardiographic and Doppler 
measurements were performed off-line on a digital work- 
station (Freeland/Prism Imaging, Broomfield, Colo.). 
Measurements of LV, mitral annular, and outflow tract 
diameters were made from two-dimensional echocardio- 
graphic images in parasternal long-axis views. LV volumes 
and ejection ffaction were calculated by means of Simp- 
son's method with two apical views. 22' 23 Stroke volume 
was calculated as the difference between the diastolic and 
systolic volumes and ejection fraction as the ratio of stroke 
volume to end-diastolic volume. Flow was calculated from 
an echocardiographically determined inflow or outflow 
diameter (d), pulsed Doppler-derived velocity time inte- 
gral (VTI) at that location, and heart rate (HR): Flow 
(cm3/min) = ~r (d/2) 2 X VTI (cm) x HR (min-l). 21 
Forward cardiac output was determined from the LV 
outflow tract diameter measured in the parasternal long- 
axis view in mid-systole, and the pulsed Doppler velocity 
time integral was measured from the apical five-chamber 
view. Mitral inflow was calculated from the annular diam- 
eter measured at the site of leaflet insertion in the 
parasternal view in mid-diastole, and the velocity time 
integral was measured from the apical four-chamber view. 
Averages of at least five cardiac ycles were used for all 
measurements of diameter and velocity time integral; ten 
cardiac cycles were averaged in the setting of atrial 
fibrillation. Heart rate was determined from an average of 
cardiac cycle lengths (R-R intervals) for the measured 
Doppler envelopes. Regurgitant volume was calculated as 
the difference between mitral inflow and forward cardiac 
output, and the regurgitant fraction was calculated as the 
ratio of the regurgitant volume to mitral inflow volume. 24 
Intraoperative and postoperative mitral gradients were 
calculated by continuous wave Doppler echocardiogra- 
phy. 
Operation. Mitral valve reconstruction was performed 
via a median sternotomy with standard cardiopulmonary 
bypass (CPB) and hypothermic, blood cardioplegic arrest 
in 12 patients. Mitral valve reconstruction was performed 
via a right thoracotomy with CPB and cold fibrillatory 
arrest in four patients who had had a previous cardiac 
operation (prior coronary bypass grafting). All operations 
were performed with institutional pproval and informed 
consent. 
Follow-up. All patients were contacted by telephone 
and personal office visit for follow-up. A standardized 
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questionnaire was used for symptomatic evaluation, in 
which physical activity was quantitated by self-report and 
compared with preoperative functional status. The pa- 
tients' personal physicians were also contacted in follow- 
up. Echocardiographic studies were generally performed 
at the University of Michigan. In the case of echocardio- 
grams performed elsewhere, original videotapes were sent 
for quantitative analysis at the University of Michigan. All 
data are presented as mean _+ standard eviation. Com- 
parison between echocardiographic and angiographic 
ejection fraction was made by means of a Pearson corre- 
lation. Comparisons between preoperative and postoper- 
ative NYHA class and LV size, volume, ejection fraction, 
regurgitant fraction, and forward cardiac output were 
made by means of paired Student's t tests. Actuarial 
survival was performed by the Kaplan-Meier method. 
Differences were considered significant at a 95% confi- 
dence limit, p < 0.05 (two-tailed). 
Results 
Sixteen patients (11 men and 5 women) were 
included in the study. Patient ages ranged from 44 to 
78 years (mean 65 + 11 years). Twelve patients had 
nonischemic dilated eardiomyopathy. Four had end- 
stage isehemic cardiomyopathy, without ongoing 
ischemia, as defined by negative dobutamine echo- 
cardiographic functional testing and negative 
positron emission tomography scanning for viability. 
Preoperatively, 14 patients had NYHA class IV 
congestive heart failure and two had class III failure. 
The mean duration of doeumented cardiomyopathy 
or symptomatic congestive heart failure was 6.6 _+ 
6.1 years (range 1 to 16 years). In the 6 months 
before the operation these patients had one to nine 
hospital admissions for congestive heart failure. 
Four patients had been previously intubated for 
pulmonary edema related to congestive heart fail- 
ure. Two patients were listed for heart ransplanta- 
tion and five others were involved in the preliminary 
workup for heart ransplantation. All patients were 
receiving maximized medical therapy for congestive 
heart failure, including digoxin, diuretics, and after- 
load reducers. Aftefload reduction was accom- 
plished with angiotensin-converting enzyme inhibitors 
in all patients, with either additional nitroglycerin or 
hydralazine in two patients each. 
Preoperative ejection fraction from left ventricu- 
lography (n = 14) or radionuclide angiography (n = 
2) ranged from 9% to 25% (mean 16% _+ 5%). 
Preoperative chocardiography was performed on 
all patients. There was good correlation between 
echocardiographically nd angiographically deter- 
mined ejection fractions (R = 0.85, p = 0.01). On 
coronary angiography, four patients with nonisch- 
emic dilated cardiomyopathy were found to have 
incidental single-vessel coronary artery disease. All 
patients with ischemic ardiomyopathy ad signifi- 
cant coronary artery disease, with prior coronary 
artery bypassing, but no ongoing ischemia on func- 
tional testing. One patient with ischemic cardio- 
myopathy had a history of recurrent ventricular 
tachycardia. One patient with nonischemic cardio- 
myopathy had hypereosinophilia syndrome and was 
receiving interferon therapy. This patient was be- 
lieved not to be a candidate for transplantation. 
At operation all patients underwent mitral recon- 
struction via remodeling ring annuloplasty, with 
implantation of a flexible remodeling ring (Duran 
ring, Medtronic, Inc., Minneapolis, Minn., or Physio 
ring, Baxter, Inc., Irvine, Calif.). No patient required 
a complex repair (i.e., leaflet resection, leaflet/ 
chordal turnover) at the time of the operation, 
inasmuch as all pätients were believed to have only 
annular dilation and/or papillary muscle dysfunc- 
tion. The average cardiopulmonary bypass time was 
149 _+ 24 minutes (range 93 to 198 minutes), with an 
aortic crossclamp time of 92 _ 11 minutes (range 81 
to 123 minutes). No pätients with irreparable de- 
fects were entered in this study. Single saphenous 
vein coronary artery bypass grafts were placed in 
four patients with incidental coronary artery disease. 
Additional procedures at the time of the operation 
included De Vega tricuspid annuloplasty in four 
patients and placement of epicardial implantable 
cardioverter defibrillator patches in one patient. 
All patients survived the mitral reconstruction 
procedure, despite their poor preoperative ntric- 
ular function. All patients were weaned from CPB 
with a phosphodiesterase inhibitor, amrinone 
(Sanofi-Winthrop, Newark, N.J.) and norepineph- 
rine. No patient required intraaortic balloon pump- 
ing or mechanical support. Intraoperative trans- 
esophageal echocardiography after annuloplasty 
and the discontinuation f CPB revealed no mitral 
regurgitation in 12 patients and trivial to mild 
regurgitation i  four. The mean transmitral gradient 
identified by intraoperative transesophageal cho- 
cardiography was 3 _ 1 mm Hg (range 2 to 6 mm 
Hg). After the mitral reconstruction, three patients 
required longer than 24 hours of mechanical venti- 
lator support but only orte patient required longer 
than 48 hours. One late superficial wound infection 
developed. No operative or hospital deaths oc- 
curred, and the mean duration of hospitalization 
after the operation was 10 +_ 4 days (range 5 to 17 
days). 
Follow-up was available for all patients. The 
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Table I. Mean LV size, volume, and flow before and after mitral annuloplasty 
P 
Preop. Postop. A * % A ~f Value 
LVIDD (mm) 72 + 9 70 + 8 -2  + 5 -3  _+ 7 0.29 
End-diastolic volume (ml) 335 - 107 307 -+ 103 -28 + 33 -8  _+ 9 0.06 
End-systolic volume (tal) 277 -+ 101 237 +_ 98 -40  _+ 39 -15 _+ 14 0.03 
Stroke volume (ml) 58 + 13 70 + 21 +12 + 10 +18 -+ 14 0.02 
Ejection fraction (%) 18 + 5 24 + 10 +6 + 6 +31 + 24 0.03 
Mitral inflow (L/min) 12.4 -+ 5.3 5.4 + 0.5 -6.9 + 5.0 -49 + 22 0.02 
Forward cardiac output (L/min) 3.2 _+ 1.0 4.7 -+ 0.9 +1.5 _+ 1.0 +52 _+ 38 0.01 
Regurgitant volume (L/min) 9.2 + 5.4 0.8 -+ 0.6 -8.4 _+ 5.4 -88.6 +- 10.1 0.01 
Regurgitant fraction (%) 70 -+ 14 15 -+ 11 -55 + 15 -79 + 15 <0.001 
Matched preoperative and 4- to 6-month postoperative echocardiographic measurements of LV function and Doppler-derived flow and volume (mean -+ 
standard eviation). The NYHA class for this group fell significantly from 3.9 - 0.4 to 1.8 -+ 0.5 (p < 0.001). LVIDD, Leit ventricular internal diameter in 
diastole. 
*A, Change from preoperative study. 
?%A, Percent change from preoperative study. 
duration of follow-up in these patients has been 1 to 
13 months, with a 1-year actuarial survival of 75%. 
At a mean follow-up of 8 months, all remaining 
patients are in NYHA class I or II, with a mean 
postoperative ejection fraction of 25%, significantly 
bettet han before the operation. In the 6 months 
before the operation these patients had one to nine 
hospital admissions for congestive heart failure. 
Postoperatively, there have been no hospitalizations 
for congestive heart failure. All patients have con- 
tinued to receive medical therapy for congestive 
heart failure, consisting of digoxin, diuretics, and 
afterload-reducing a ents. However, drug dosages 
tended to be lower in the postoperative period. In 
no case was a patient receiving a higher dose of any 
medication for heart failure in the postoperative 
period than in the preoperative r gimen. Finally, the 
diuretic dose required has been reduced by more 
than twofold. All patients have remained in their 
preoperative rhythm, 11 in normal sinus rhythm and 
five in atrial fibrillation. 
All patients reported subjective improvement in
their functional status after the operation, citing 
activities routinely performed for which exertional 
dyspnea was previously prohibitive. The NYHA 
failure class significantly decreased for every patient 
individually and from a mean of 3.9 + 0.2 to 1.8 + 
0.4 for the group. 
Follow-up echocardiography at 1 week and 4 to 6 
months was available for all patients. At 1 week 13 
patients had no mitral regurgitation and three had 
mild regurgitation. The mean transmitral gradient 
on follow-up at 1 week was 3 + 1 mm Hg (range 1 
to 5 mm Hg). Matched preoperative and 4- to 
6-month postoperative measurements of LV size 
and Doppler-derived flow and volume are summa- 
rized in Table I. All patients had a marked reduction 
in regurgitant volume and regurgitant fraction and 
significantly improved LV ejection fraction, end- 
diastolic volume, and end-systolic volume. 
Three late deaths have occurred in this group 
after mitral valve reconstruction. One late death 
occurred related to complications of cholecystec- 
tomy, 7 months after mitral reconstruction i  a 
patient who was inadvertently removed from the 
majority of the heart failure medicines. The second 
late death occurred from continued ventricular fail- 
ure 6 months after mitral valve reconstruction, 
despite no mitral regurgitation noted on numerous 
follow-up echocardiographic studies. The third late 
death occurred 2 months after the operation and 
was a witnessed sudden death, presumed to be from 
a ventricular arrhythmia in a patient who was doing 
well. 
Discussion 
Mitral regurgitation is a poor prognostic sign for 
patients with end-stage cardiomyopathy. In one 
study of 91 patients with dilated cardiomyopathy, 
those patients with mitral regurgitation (by two- 
dimensional color Doppler echo¢ardiography) ad a 
significantly decreased survival at 2 years of fol- 
low-up versus those patients without mitral regurgi- 
tation (20% versus 60%). 5 This deleterious effect 
was most influential in patients with severe mitral 
regurgitation but was even evident in patients with 
mild mitral regurgitation. Additionally, in a recent 
study, long-term survival and prognostic factors for 
dilated cardiomyopathy were studied in 111 pa- 
tients. Actuarial predictors of survival revealed that 
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mortality was related to ejection fraction less than 
30%, episodes of heart failure, and increased LV 
end-diastolic volume. 2s In a further study of 130 
patients awaiting transplantation, 1-year survival 
was only 46%. Significant independent predictors of 
death for these patients with idiopathic eardiomy- 
opathy were low forward stroke volumes, an ejection 
fraction less than 25%, and mitral regurgitation. 26 
All of these negative prognostic factors were present 
in our study population of cardiomyopathy with 
secondary mitral regurgitätion and would predict a 
poor 1-year survival. 
Surgical correction of mitral regurgitation and 
accompanying volume overload has been shown to 
be warranted for patients with mitral regurgitation 
and could be most beneficial in this group of pa- 
tients with cardiomyopathy and secondary mitral 
regurgitation. In a study of 249 patients with mitral 
regurgitation who had angiographic assessment of
LV function before the operation, survival of surgi- 
cally treated patients was significantly better than 
that of medically treated patients. Those patients 
with mild to moderate impairment of ejection frac- 
tion were most responsible for the improved survival 
in surgieally treated patients, which occurred espite 
greater functional and hemodynamic impairment in
surgically treated patients before the operation. 14
Unfortunately, many surgical studies have also 
denoted that greater functional and hemodynamic 
impairment and reduced ejection fraction equate 
with poor operative and in-hospital survival in pa- 
tients operated on for mitral regurgitation by mitral 
valve replacement. 8' 13-15, 27 The high operative mor- 
tality and poor outcome have inhibited the routine 
undertaking of surgical correction for mitral regur- 
gitation in patients with extremely poor LV func- 
tion. These findings are in accordance with those of 
many experimental laboratory studies demonstrat- 
ing that chordal transection results in significant 
reductions in rest and exercise ejection fraction, 
caused by a significant increase in end-systolic cir- 
cumferential wall stress and geometric distortion. 9q2 
One study notes that loss of annular-chordal-papil- 
lary continuity immediately decreases LV systolic 
function by 30%, alters the twist mechanics of 
myocardial contraction, and results in a globular, 
inefficient geometry of the heart. 9-12 
However, many studies have shown that mitral 
reconstruction, as opposed to replacement, results 
in improved rest and exercise ejection indexes, 
primarily the result of a marked reduction in end- 
systolic stress and maintenance of a more ellipsoidal 
chamber geometry. 2s' 29 Many clinical studies have 
compared the results of mitral valve reeonstruction 
with those of mitral valve replacement and have 
concluded that the preservation of the annular- 
chordal-papillary muscle continuity results in main- 
tenance of LV function and geometry, leading to 
better patient outcome. 17-2°' 30 
On the basis of the poor natural history of this 
population with end-stage cardiomyopathy, mitral 
regurgitation, and heart failure resistant to medical 
therapy, for whom heart transplantation has previ- 
ously been the only therapy available, mitral recon- 
struction was believed to be a new and viable option. 
Teehnically, mitral reconstruction via annuloplasty 
effectively corrected mitral regurgitation i these 
patients, confirmed both on intraoperative trans- 
esophageal echocardiography and on follow-up 
transthoracic studies. Furthermore, despite high op- 
erative risks, there were no operative or in-hospital 
deaths and the actuarial survival was 75% at 1 year. 
Not only was survival improved but functional 
status has changed remarkably in these patients. 
Importantly, no patient has had a worsening clinical 
status during follow-up. Additionally, echocardio- 
graphic analyses revealed a strong trend toward 
decreased LV volume after the operation, with 
significant increases in ejection fraction and forward 
cardiac output. Improvement in echocardiographic 
parameters of ventricular function were not neces- 
sarily anticipated, because LV function has been 
shown to decrease after mitral valve replacement, 
presumably asa result of loss of chordal attachments 
and normal systolic ventricular shortening. Second, 
loss of the low-impedance left atrial chamber asso- 
ciated with correction of mitral regurgitation might 
be expected to lead to further systolic impairment in
the setting of preexisting ventricular dysfunction. 
However, LV function improved after the operation 
in these patients. This improvement implies that a 
component of ventricular decompensation observed 
before the operation was due to volume overload 
associated with severe mitral regurgitation superim- 
posed on dilated cardiomyopathy. Postulated mech- 
anisms for the improvement in ventrieular function 
include stabilization of the mitral anulus and LV 
unloading that has induced a more favorable ven- 
tricular geometry. A recent study denotes that re- 
modeling of LV geometry may be rapid and eom- 
plete in patients with resultant regurgitant fractions 
of less than 30% after correction of mitral regurgi- 
tation. 31 Out patients had a mean residual regurgi- 
tant fraetion of only 16% after the operation, which 
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could favor rapid LV remodeling. Furthermore, 
there is evidence from recent trials with a left 
ventricular assist device that unloading the dilated 
cardiomyopathic LV encourages ventricular ecov- 
ery. 32 A second mechanism ay involve correction 
of mitral regurgitation, decreasing the volume over- 
load of the LV and establishing a better position on 
the Frank-Starling curve. 
Mitral valve reconstruction for mitral regurgita- 
tion complicating dilated cardiomyopathy as been 
previously reported in only a single patient, 33 who 
had significant ischemic disease. Each patient in- 
cluded in our present study had dilated cardiomy- 
opathy with advanced symptoms of congestive heart 
failure despite aggressive medical therapy, a poor 
prognostic sign for patients with end-stage disease. 34 
Mitral reconstruction performed in this cohort re- 
sulted in significant improvement in survival and 
symptomatic status on early follow-up and was 
associated with favorable changes in ventricular size 
and function. Although longer term follow-up with 
greater numbers of patients and perhaps case- 
matched controls are necessary, this pilot study 
demonstrates the feasibility of operative repair for 
correction of mitral regurgitation, with an excellent 
technical outcome and a low operative mortality. 
Other aspects of follow-up for these patients, includ- 
ing assessment of maximum oxygen consumption 
during exercise and LV remodeling, are being un- 
dertaken at present. Finally, the effect on need for 
transplantation, the ability to perform transplanta- 
tion in these patients, and the cost-effectiveness 
versus transplantation remain to be answered. How- 
ever, we are encouraged by these early results and 
believe that mitral reconstruction ffers a new strat- 
egy for patients with end-stage cardiomyopathy. 
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Discussion 
Dr. Vaughn A. Starnes (Los Angeles, Califi). It would 
not have been intuitively obvious to me that these patients 
would have benefited from this operation. To summarize 
some of the demographics, the group comprised an older 
population, mean age 65 years, with severe heart failure 
(class IV) who had been symptomatic for more than 6 
years. During the prior 6 months these patients had been 
hospitalized six to nine times. The patients had dilated 
cardiomyopathy with an average jection fraction of 16% 
and 4+ mitral regurgitation. The authors repaired the 
mitral valve to get rid of the mitral regurgitation and 
"improve" the ejection fraction. Their results are surpris- 
ingly good. 
The actuarial survival is 75%. To put this in perspective, 
reports from the literature indicate a 2-year survival of 
only 20%. Clearly this operation has extended the survival 
time of this group of patients. Transplantation offers a 
better 1-year survival, around 80% to 90%, but donor 
shortage is a real problem. 
This operation decreased the systolic volume by 15%, 
increased the ejection fraction from 16% to 25%, and 
increased the cardiae output on the average by 35%. 
These are truly surprising results. 
Dr. Bolling, how do you account for the improvement i  
LV function after the repair of a regurgitant lesion in a 
patient with severe cardiomyopathy? Is it due to remod- 
eling or is it due to some other factor yet undetermined? 
Do you have any echocardiographic data to support he 
idea of remodeling? 
Dr. Bolling. We do have preliminary echocardiographic 
data on remodeling, and I think that is occurring. We 
thought hat the ejection fractions would not change and 
that if we could get the/najority of the patients through 
the operation perhaps their systolic function would not 
improve, but their forward flow would. Despite that 
hypothesis, the ejection fractions improved. 
Regarding long-term remodeling, Dr. Frasier reported 
on a patient who was supported for 550 days by the 
HeartMate device (Thermo Cardiosystems, Inc., Woburn, 
Mass.) and died of a stroke when the HeartMate left 
ventricular assist deviee was turned oft. The ejection 
fraction had increased from about 12% up to about 45%, 
and the patient was sustained by his own heart. Whether 
this is long-term change attributable to LV remodeling 
and whether that will be sustained under a heavier load, 
we do not know. 
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We are interested in calcium handling of the myocyte, 
and we are investigating that right now. 
Dr. Starnes. What are the acute hemodynamic effects of 
pulmonary artery wedge pressures in these patients in the 
immediate postoperative period? 
Dr. Bolling. Left ventricular end-diastolic pressures and 
wedge pressures do not change acutely. These patients are 
rar out on the Starling curve. In the immediate postoper- 
ative period, if they have a wedge on a left ventricular 
end-diastolic pressure of 25 to 35 mm Hg, they need to be 
at that pressure. However, their pulmonary pressures drop 
and, as in the transplant population, they continue to 
drop. In some of these patients the pulmonary pressures 
are dramatically lower at 1 year's follow-up. 
Dr. Starnes. Your results certainly lead one to consider 
this operation as a bridge to transplantation. Seven of 
your patients were actually being evaluated for transplan- 
tation, and two have been accepted onto your transplant 
list. Are you considering such an option for some of your 
patients? 
Dr. Bolling. These are very early results and we cer- 
tainly do not want to overstate them. In fact, I would 
rather understate the results. However, I think for some 
patients this operation could be a bridge to transplanta- 
tion. For some it may obviate the need for transplantation. 
Dr. Joseph Cleveland (Missoula, Mont.). Could you 
amplify some of the details of the reconstructions, such as 
the exact ype of ring and whether you resected any of the 
posterior leaflet? Did you simply put in a ring? What was 
the average size of the ring? 
Dr. Bolling. We have extensive xperience with mitral 
valve reconstruction at our institution; however, these 
patients were picked because they had no primary mitral 
disease. They merely had annular dilatation. None of the 
patients had chordal transfers or leaflet resection. All 
received aflexible ring, either the Medtronic Duran or the 
Baxter Physio ring. We undersized the trigone-to-trigone 
distance, believing that we probably would not induce 
stenosis because these patients had normal mitral subval- 
vular apparatuses. Our postoperative data bear out that 
belief. At 6 months' follow-up for the majority of these 
patients, they do not have mitral stenosis. We undersized 
the rings perhaps by one size. The average size ring that 
we inserted in these patients was a 29 mm ring. 
Dr. D. Craig Miller (Stanford, Calif.). Let me go farther 
than Dr. Starnes in terms of surprise. I am flabbergasted. 
These results are absolutely phenomenal. Why? Your 
radionuclide nd-diastolic volumes were about the same 
pre- and post-load. Do you have any M-mode echocardio- 
graphic data to teil us what happened over time to 
end-diastolic dimension, end-systolic dimension, and LV 
shape? 
Dr. Boiling. We do have that information, but it was not 
presented here. However, with further follow-up, most of 
the patients now have end-diastolic volumes that clearly 
are smaller. We are just as surprised as everyone lse, but 
I think our series has to stand by itself. Again, I would like 
to understate the series, not overstate it. 
Dr. Miller. They are indeed smaller ventricles, but are 
they also more elliptical ventricles after the operation? 
Dr. Bolling. Definitely. In fact, some of our echocardio- 
logists, who were assessing the echocardiograms in a blind 
fashion, had to check the name of the patient for fear that 
they were reading the wrong echocardiogram. In one of 
our patients the ejection fraction increased from 15% to 
44%. 
Dr. Miller. Before we accept the increase in stroke 
volume and ejection fraction, what was the afterload 
during both studies, as estimated by systolic, mean, or 
diastolic blood pressure? I trust it was the same, because 
a discrepancy could certainly confound your data. 
Dr. Bolling. All those are the same afterload reduc- 
tions. In fact, the patients were studied prospectively, so 
the echocardiograms were done on an outpatient basis by 
the same echocardiologist with the same afterload and the 
same mean arterial blood pressure. 
Dr. Edward Verrier (Seattle, Wash.). There has to be 
something unique about this group of patients. The 
most striking point is the 6.6-year period of therapy for 
chronic heart failure with some stability. According to 
the numbers that Dr. Starnes alluded to, these patients 
should have all been dead. Is part of the take-home 
message that this longer period of stability is necessary? 
We are not going to get the same results if we start 
applying this technique in anybody with an ejection 
fraction of 12%. 
Dr. Bolling. I totally agree. If we applied this technique 
to every patient with an ejection fraction of 12%, we 
would have a horrendous operative mortality. However, 
these patients had the cardiologists totally frustrated 
because they were stable and then suddenly became 
unstable. These were the patients who could not be kept 
out of the hospital. One patient was admitted and dis- 
charged nine times in 6 months. We postulated that this 
might be a volume overload problem. Perhaps these are 
patients in whom failure accelerates rapidly, and we are 
catching them right at the end. 
Dr. John Benfield (Sacramento, Calif.). One of the 
things that we have learned in clinical trials of patients 
with lung cancer is that the patients we enter into proto- 
cols and studies are not necessarily the same as those 
whom we do not enter into the protocols. Therefore, one 
must be very careful in interpreting results as representing 
a step forward unless one knows the full denominator of 
patients from whom we choose the ones we select for 
operation. Therefore, my question is this: Improved sur- 
vival compared with what? Were these patients truly 
representative? How were they selected? 
Dr. Bolling. No patient was turned down who met these 
criteria, but I think you are right. The patients who never 
came to us are probably a more interesting roup. That 
brings up the need to do case-matched controls. All we 
had were the historical controls from the three large series 
that predicted terrible 1- and 2-year survivals for this 
group of patients with end-stage dilated cardiomyopathy 
and severe uncontrollable mitral regurgitation. This pilot 
study was more for operative feasibility: Could we operate 
on these patients? Could they survive the operation? I 
agree that case-matched controls are the next logical step 
to be taken in this group. 
